Sporos Bioventures, LLC, a Houston, TX-based company formed to catalyze the development of therapies that target novel disease mechanisms in cancer and immune diseases, closed a $38.1m Series A financing.
The company plans to use the proceeds to support the development of lead assets across its portfolio and build out the team.
Sporos identifies novel disease mechanisms and strategically deploys talent, capital and access to operational resources to catalyze the development of breakthrough medicines. Its current pipeline is diversified across four entities and includes multiple clinical-stage candidates that are being investigated for the treatment of multiple indications in cancer and immune disease.